Compare Heron Therapeutics Inc (HRTX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Procter & Gamble Co — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Procter & Gamble Co trades at $147.99 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 3796.9× Heron Therapeutics Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PG | |
|---|---|---|
Market Cap | $91.46M | $347.26B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $167.18 |
52-Week Low | $0.39 | $138.10 |
Enterprise Value | $189.36M | $372.74B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Procter & Gamble (PG) trades at $148.00, down 1.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent developments include a partnership with the WNBA and ongoing dividend payments.
PG offers stable growth and reliable dividends, supported by strong cash flow and a 69-year dividend increase streak. Risks include premium valuation multiples and soft demand pressures. Analyst consensus is bullish with a $161.71 price target, suggesting potential upside from current levels amid moderate market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
